MEMPHIS, Tenn. — Active Implants Corporation (AIC), a pioneer in pliable
orthopaedic implant technology, today announced CE Mark approval for its novel
low wear, polymer hip implant which allows the sale of the product throughout
The AIC Hip Buffer(TM) is a press-fit, low wear polycarbonate polyurethane
acetabular cup. This acetabular implant allows for larger femoral head sizes
that should enhance joint stability and improve range of motion and shock
absorption. The AIC Hip Buffer(TM) has potential applications in both total hip
(complete replacement of the joint) and hip resurfacing (replacement of just the
surface) surgical procedures, providing a less invasive implant with low wear
metal-polymer characteristics. The company will implement a post-approval
controlled release of the Hip Buffer(TM).
The AIC Hip Buffer(TM) introduces advanced low wear, pliable materials and
innovative implant designs that are less invasive, bone sparing and expected to
restore closer to normal joint function. The materials used by AIC are at least
50 times more pliable than all other materials used for this application and can
allow for a better and more normal stress transfer to surrounding bone.
"We view this as disruptive technology and are pleased with our progress working
closely with leading orthopaedic surgeons on establishing the clinical safety
and efficacy of our novel implant technology" said Stephen Bradshaw, President
and Chief Executive Officer of AIC. "Following more than a decade of research
and development work, the Hip Buffer(TM) marks the beginning of a new generation
of resilient implant solutions with a potential broad range of applications in
the extremity joints and spine."
About Active Implants Corporation
Active Implants Corporation is a privately-held company formed in 2004 by an
experienced team of orthopaedic executives and inventor with vast experience in
advanced, pliable materials. AIC owns a robust intellectual property estate of
innovative implant solutions and minimally invasive surgery technology with a
potential broad range of medical applications. Headquartered in Memphis,
Tennessee, the mission of the company is to serve the emerging "Interventional
Arthroplasty" market by providing earlier in life orthopaedic implant solutions.